Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia. The American journal of the medical sciences [Am J Med Sci] Journal article | | Title | Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia. | | Author(s) | Annane D, Decaux G, Smith N, FOR THE CONIVAPTAN STUDY GROUP | | Institution | From the Department of General Critical Care Medicine/Division of Acute Medicine and Surgery, University of Versailles SQY Raymond Poincaré Hospital (da), Garches, France; Department of Internal Medicine, Erasme University Hospital (gd), Bruxelles, Belgium; and Astellas Pharma US, Inc. (ns), Deerfield, Illinois. | | Source | Am J Med Sci 2008 Dec 3. | | Abstract | BACKGROUND:: In most cases of hyponatremia, arginine vasopressin secretion is inappropriately high. This placebo-controlled, randomized, double-blind multicenter study evaluated the efficacy and safety of oral conivaptan, a V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia.
METHODS:: Eighty-three patients with serum [Na] less than 130 mEq/L were stratified by volume status and randomly assigned to placebo or conivaptan 40 or 80 mg/d for 5 days.
RESULTS:: Conivaptan increased the baseline-adjusted area under the serum [Na]-time curve significantly more than placebo (P = 0.0001). Patients given either dose of conivaptan demonstrated a serum [Na] of 4 mEq/L or greater above baseline significantly faster than those given placebo (P < 0.001) and maintained that increase for a greater total time (P = 0.0001). The least squares mean change in serum [Na] from baseline to end of treatment was also significantly greater with conivaptan 40 and 80 mg/d (6.8 and 8.8 mEq/L, respectively) (P = 0.0001) than that with placebo (1.2 mEq/L). The percentage of patients who obtained an increase from baseline in serum [Na] of 6 mEq/L or greater or normal serum [Na] was significantly higher among patients given conivaptan 40 and 80 mg/d (67% and 88%, respectively) than among those given placebo (20%; P < 0.001). Conivaptan was well tolerated; the most frequent adverse events were urinary tract infection, anemia, pyrexia, cardiac failure, hypotension, and hypokalemia.
CONCLUSION:: Oral conivaptan was effective in increasing serum [Na] in patients with euvolemic or hypervolemic hyponatremia and had a favorable safety profile. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19057376 |
|
|
| |
Advertise on this site.
| | |
|
